Geron Corporation

11/21/2024 | Press release | Distributed by Public on 11/22/2024 11:20

Sustained Benefits of Imetelstat on Patient reported Fatigue in Patients With Lower risk Myelodysplastic Syndromes Ineligible for, or Relapsed/refractory to, Erythropoiesis[...]

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.